Key facts
- EarLens’s last known valuation is $23.0M (Feb 2025).
- It has raised $330.6M across 11 recorded rounds; the latest was Early Stage VC ($8.0M) in Feb 2025.
- Notable investors include EXOR Seeds, Lightstone Ventures, Richard King Mellon Foundation, KCK Group, Far East Capital (Singapore) — 24 tracked in total.
- EarLens has filed 17 Form Ds with the SEC since 2010, most recently Mar 2025 ($8.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 11 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for EarLens
Funding rounds
11 roundsAbout EarLens
Developer of a contact hearing technology device designed to change the current standard of care for sound performance. The company's device utilizes low-frequency radio and a small lens placed on the eardrums to directly activate the natural hearing system and automatically adjusts to challenging listening environments with natural sound and minimal feedback, enabling hearing-impaired patients to hear clearly while minimizing the potential for feedback.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2005
- Employees
- 108
- Website
- earlens.com/
- Ownership
- Privately Held (backing)
EarLens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EarLens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EarLens in its N-PORT filings yet. We sweep new filings monthly.